The company will present five abstracts on recent research, alongside its academic partners
OptiBiotix Health, a scientific pioneer in microbiome modulation technology, will demonstrate its new advancements in prebiotic and probiotic ingredient research at Probiota 2023.
The company will present five abstracts on recent research, alongside its academic partners from the University of Roehampton and the University of Southampton at the event’s Scientific Frontiers session. These will be displayed as posters during the three-day summit, which takes place in Barcelona, Spain, from 6 – 8 February.
Stephen O’Hara, CEO of OptiBiotix, commented: “Probiota and the IPA World Congress is one of the top events for the prebiotic, probiotic and microbiome industries. We are looking forward to sharing our latest science-backed research on ingredients such as LeanBiome, WellBiome and LPLDL during the conference to key opinion leaders and academia.”
For its functional fibres division, OptiBiotix will demonstrate three abstracts. These include the impact of its sports nutrition ingredient, LeanBiome, on body composition, hunger, cravings and gut microbiome composition via multiple human intervention studies, alongside presenting how its synergistic prebiotic formulation, WellBiome can optimise gut microbiome diversity in an ageing population.
Probiota and the IPA World Congress is one of the top events for the prebiotic, probiotic and microbiome industries
To complement the above, the company’s subsidiary – ProBiotix Health – will also demonstrate its latest research on Lactobacillus plantarum, LPLDL. In its latest peer-reviewed study published last year, the FDA-affirmed GRAS probiotic strain probiotic strain was shown to reduce key cardiovascular risk markers, including total cholesterol by up to 34.6%, LDL cholesterol by 28.4% and Apolipoprotein B by 28.6%.
In addition, the company will also exhibit its findings on the synergistic development of a synbiotic, which targets Lactobacillus in a bid to reduce cholesterol.
“In addition to presenting our abstracts, we are acutely interested in how key industry players are using the gut-brain axis as an opportunity for the development of mood, stress and sleep supplements,” continued O’Hara. “OptiBiotix is currently conducting a joint research project with the FEM Research Institute in Italy, the University of Southampton and the University of Leeds in the UK to understand how our microbiome modulators could improve these factors to aid overall health and wellbeing. Attending Probiota is an ideal way to share our insight into this rapidly growing area in microbiome research.”
Probiota 2023 will welcome speakers from a range of revered institutions discussing topics such as the rise in pharmabiotics, synbiotics, and postbiotics. Its scientific frontiers session invites authors from all parts of the world to submit abstracts, which are reviewed by a team of scientific experts, and takes place across all three days.